The committee's role is to guide the continued development, training, and advocacy of the AMCP Format for Formulary Submissions, including related materials and revisions.
The committee’s role is to identify developments at the state & federal levels regarding managed care pharmacy and to develop strategies regarding consistent with the AMCP mission.
The committee’s role is to oversee strategies consistent with the mission of the Academy in order to maintain a viable and growing membership.
June 2019 News & Views: Educational Affairs Committee Plans Nexus 2019; Cathy Carroll Fund Now Receiving Donations; Cantrell Quoted in Washington Post; AMCP Releases Concepts for Effective PA Practices
The Joint Research Committee encourages the creation and dissemination of relevant research and initiatives to advance patient care services in managed care pharmacy.
The committees of AMCP are extremely active and the building blocks for the organization. Learn more about what it means to be a committee member.
The committees of AMCP are the building blocks for the organization and their work is essential to moving AMCP and its strategic plan forward.
The committee’s role is to assist in the promotion and education of managed care pharmacy principles and to increase the awareness of AMCP.
The Audit Committee reviews the audit and the company’s process for monitoring compliance with laws, regulations and agreements.
The committee’s role is to define & evaluate the practices of managed care pharmacy and to develop guidelines specific to those practices consistent with the AMCP mission.
May 2019 News & Views: Survey Identifies Barriers and Solutions to Biosimilar Adoption; In Memoriam: Past President Cathy Carroll; CEO Blog: PAs Play Key Role in Appropriate Medication Use; PGY1 Residents First to Rotate at AMCP/Foundation Headquarters
From April 2019 News & Views: The Biologics Price Competition and Innovation Act (BPCIA) of 2009 created an FDA approval pathway for biosimilars that aimed to expanded patient access to these more affordable therapies. But formidable barriers, including concerns about safety and efficacy among prescribers and state laws on substitution and interchangeability, have hindered biosimilar adoption.
